Table 2 Pharmacokinetic parameters for sitagliptin and dorzagliatin, measured at steady state, after the last dose in a 5-day interval of sitagliptin only, dorzagliatin only, or sitagliptin + dorzagliatin treatment

From: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity

 

Geometric mean

GMR (90% Cl)

Sitagliptin alone

Sitagliptin + Dorzagliatin

Dorzagliatin alone

Sitagliptin

    

Cmax (ng/mL)

410

403

/

98.14 (83.73–115.03)

AUC0–24h (ng*h/mL)

2938

2722

/

92.63 (85.61–100.22)

Dorzagliatin

    

Cmax (ng/mL)

/

833

814

102.34 (86.92–120.50)

AUC0-24h (ng*h/mL)

/

6593

6571

100.34 (96.08–104.79)

  1. Cmax maximum plasma concentration, AUC0–24 area under the concentration-time curve from 0 to 24 h, GMR adjusted geometric mean ratios (combination/monotherapy ratio), CI confidence interval.
Back to article page